Develops therapeutic proteins and antibodies that act on cell-surface receptors, pursuing medicines for people with pulmonary hypertension and hereditary hemorrhagic telangiectasia.
10-K for FY2025, filed Feb 26, 2026We are a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate…View ↗
Our lead asset, TX45, is an Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. Relaxin…View ↗
Our second product candidate, TX2100, is a VHH-Fc fusion antagonist antibody that binds to the APJ receptor (also known as the apelin…View ↗
From gene therapy to biologics
The business shifted from developing gene therapies made from patients’ own stem cells for rare genetic diseases to developing therapeutic proteins and antibodies that target GPCRs, including candidates for pulmonary hypertension and hereditary hemorrhagic telangiectasia.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Feb 26, 2026We are a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate…View ↗
Our lead asset, TX45, is an Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. Relaxin…View ↗
Our second product candidate, TX2100, is a VHH-Fc fusion antagonist antibody that binds to the APJ receptor (also known as the apelin…View ↗
Competes with AstraZeneca, Vaderis, Terremoto, Atavistik, Diagonal Therapeutics, Alnylam Pharmaceuticals, Boehringer Ingelheim, Novartis, Septerna, SOSEI-Heptares, Structure Therapeutics, Abalone Bio, Orion Biotechnology, Abilitia Bio, Confo Therapeutic, Omeros, and GPCR Therapeutics
10-K for FY2025, filed Feb 26, 2026We face competition from companies that are pursuing development of engineered proteins or small molecule agonists of relaxin including…View ↗
Loading...